Q4 2025 · 13F-HR
SECTOR GAMMA ASholdings as filed
Filed 2026-02-12 · accession 0000945621-26-000283
$438.7M
Reported value
36
Positions
2025-12-31
Period end
The Brief · SECTOR GAMMA AS · Q4 2025
AI · grounded in 13F
SECTOR GAMMA AS exited its position in BAX, reducing its holdings by $8.69M. The fund also closed positions in VTRS and HUM, totaling losses of $6.62M and $6.23M respectively. On the buy side, the fund established new positions in REGN for $5.53M and CRNX for $5.35M. Additionally, the fund increased its stake in ELV by 238.91%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $40.2M | 9.17% | 745,955 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $38.3M | 8.73% | 363,651 | Common | SOLE |
| G5960L103 | MDT | MEDTRONIC PLC | $25.9M | 5.90% | 269,644 | Common | SOLE |
| 075887109 | BDX | BECTON DICKINSON & CO | $25.7M | 5.86% | 132,376 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $21.7M | 4.94% | 176,414 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $21.6M | 4.93% | 218,783 | Common | SOLE |
| 717081103 | PFE | PFIZER INC | $21.4M | 4.88% | 859,539 | Common | SOLE |
| 031162100 | AMGN | AMGEN INC | $20.0M | 4.55% | 60,956 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $15.0M | 3.43% | 85,475 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $14.6M | 3.34% | 184,977 | Common | SOLE |
| 126650100 | CVS | CVS HEALTH CORP | $14.1M | 3.21% | 177,599 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $12.7M | 2.90% | 61,946 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC INC | $12.6M | 2.86% | 21,688 | Common | SOLE |
| 116794108 | BRKR | BRUKER CORP | $12.0M | 2.73% | 254,697 | Common | SOLE |
| 98956P102 | ZBH | ZIMMER BIOMET HOLDINGS INC | $11.9M | 2.72% | 132,478 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $11.8M | 2.69% | 198,505 | Common | SOLE |
| 036752103 | ELV | ELEVANCE HEALTH INC FORMERLY | $11.4M | 2.60% | 32,546 | Common | SOLE |
| 15135B101 | CNC | CENTENE CORP DEL | $10.6M | 2.42% | 258,109 | Common | SOLE |
| 36266G107 | GEHC | GE HEALTHCARE TECHNOLOGIES I | $9.4M | 2.14% | 114,390 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $8.2M | 1.87% | 96,402 | Common | SOLE |
| 05352A100 | AVTR | AVANTOR INC | $8.0M | 1.82% | 695,403 | Common | SOLE |
| 090572207 | BIO | BIO RAD LABS INC | $7.2M | 1.64% | 23,750 | Common | SOLE |
| 504922105 | LH | LABCORP HOLDINGS INC | $6.8M | 1.55% | 27,019 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $6.2M | 1.42% | 93,823 | Common | SOLE |
| 875372203 | TNDM | TANDEM DIABETES CARE INC | $5.9M | 1.34% | 267,091 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $5.5M | 1.26% | 7,165 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $5.4M | 1.22% | 115,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $5.3M | 1.21% | 252,062 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $5.1M | 1.15% | 76,122 | Common | SOLE |
| 40412C101 | HCA | HCA HEALTHCARE INC | $5.0M | 1.15% | 10,784 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $4.7M | 1.08% | 455,841 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $4.7M | 1.07% | 61,923 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $3.5M | 0.79% | 16,305 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $2.2M | 0.49% | 52,039 | Common | SOLE |
| 68622V106 | OGN | ORGANON & CO | $2.2M | 0.49% | 300,000 | Common | SOLE |
| 15687V109 | CERT | CERTARA INC | $2.0M | 0.46% | 230,565 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.